John Green vs. Johnson & Johnson (part 2)
Listen now
Description
This is part two of our globe-spanning story about drugs, patents, and YouTube megastar John Green.  Quick recap: In our last episode, we learned how writer and YouTube star John Green kicked up a fight with Johnson & Johnson over a medicine called bedaquiline. And appeared to score a victory. Here, we dig into the backstory: How everything John Green and his fans won was built on activism going back 20 years, and spanning multiple continents.  All of it illustrates how pharma companies work the patent system to extend their legal monopolies on medicine way beyond the standard 20 years, and how that leads to high drug prices here and abroad.  And what we can maybe do about it.  This episode starts in 2004, when India began the process of changing its patent laws to align with global trade rules. Activists there managed to carve out exceptions to the law to prevent some of the worst patent abuses.  Fast forward to this year, when those legal safeguards become key to unlocking new doors in the fight against TB.  Meanwhile, the proponents of those Indian safeguards are here in the U.S., pushing for drug patent reform here. Which not only could help Americans, but also influence global standards.  Here's a transcript of this episode.  Send your stories and questions. Or call 724 ARM-N-LEG. And of course we'd love for you to support this show. Hosted on Acast. See acast.com/privacy for more information.
More Episodes
We’re launching a brand new project and need your help! We’re zooming in on charges that are becoming more and more common on your medical bills: facility fees.  Facility fees are charges tacked onto your bill for visiting a doctor’s office or clinic related to a hospital or larger health care...
Published 05/02/24
Published 05/02/24
When a subsidiary of the giant UnitedHealth Group got hit by a cyberattack recently, a big chunk of the country’s doctors, pharmacists, hospitals and therapists just stopped getting paid.  It’s been a huge disruption, with some providers wondering if they can keep their doors open. But thanks to...
Published 04/11/24